Anzeige
Mehr »
Login
Freitag, 02.05.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Glencore, Teck - und jetzt Forge? Dieses Junior-Unternehmen könnte der cleverste Kohle-Trade 2025 sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JKUU | ISIN: NO0010205966 | Ticker-Symbol: N1A
Frankfurt
30.04.25
21:50 Uhr
1,825 Euro
+0,030
+1,67 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NAVAMEDIC ASA Chart 1 Jahr
5-Tage-Chart
NAVAMEDIC ASA 5-Tage-Chart
PR Newswire
212 Leser
Artikel bewerten:
(1)

Navamedic ASA: Annual Report 2024

Finanznachrichten News

OSLO, Norway, April 30, 2025 /PRNewswire/ -- Navamedic ASA has today published its Annual Report for 2024. Find enclosed the report in PDF as well as an ESEF file version. The report is also made available at the company's website at https://navamedic.com/investors/annual-reports/

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing.

Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/navamedic-asa/r/navamedic-asa--annual-report-2024,c4143971

The following files are available for download:

https://mb.cision.com/Main/17619/4143971/3422860.pdf

Navamedic Annual Report 2024

https://mb.cision.com/Main/17619/4143971/3422861.zip

NavamedicASA-2024-12-31-0-en.zip

Cision View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-annual-report-2024-302443095.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.